Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total transaction of $27,198.00. Following the sale, the director now owns 600 shares of the company’s stock, valued at approximately $27,198. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) traded up $1.73 during midday trading on Friday, hitting $45.05. 507,620 shares of the stock were exchanged, compared to its average volume of 403,906.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The company had revenue of $7.80 million during the quarter, compared to analyst estimates of $8.32 million. During the same period in the previous year, the company earned ($0.49) EPS. The company’s quarterly revenue was down 16.1% compared to the same quarter last year. equities analysts predict that Five Prime Therapeutics, Inc. will post -5.5 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.watchlistnews.com/william-r-ringo-sells-600-shares-of-five-prime-therapeutics-inc-fprx-stock/1678408.html.

Several brokerages have recently issued reports on FPRX. Royal Bank Of Canada began coverage on shares of Five Prime Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $41.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $52.00 price objective (down from $55.00) on shares of Five Prime Therapeutics in a research note on Thursday, August 10th. Zacks Investment Research lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. BidaskClub lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $39.00 price objective on shares of Five Prime Therapeutics in a research note on Friday, September 22nd. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $54.83.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning lifted its position in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 54 shares during the last quarter. Rockefeller Financial Services Inc. acquired a new stake in shares of Five Prime Therapeutics during the second quarter worth about $210,000. Tudor Investment Corp ET AL lifted its position in shares of Five Prime Therapeutics by 56.8% during the first quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 2,910 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Five Prime Therapeutics during the third quarter worth about $341,000. Finally, Legal & General Group Plc lifted its position in shares of Five Prime Therapeutics by 39.2% during the first quarter. Legal & General Group Plc now owns 9,168 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 2,583 shares in the last quarter. 84.01% of the stock is currently owned by institutional investors.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.